Question explored with the scientific record
Conversation so far
- 1 What does an aluminum adjuvant do?
- 2 Do HpV vaccines prevent cervical cancer?
Answered on this page ↓
Do HpV vaccines prevent cervical cancer?
The short version: for girls vaccinated at 12 or 13, the evidence shows a large reduction in cervical cancer. For older women, the evidence is much weaker.
The strongest data come from England. Women offered routine vaccination at age 12 or 13 had 83.9% fewer invasive cervical cancers than women never offered it, and 94.3% fewer cases of CIN3, the highest-grade precancer [3]. The same study estimated 687 cancers and 23,192 CIN3 cases prevented by mid-2020 [3]. That is a real clinical outcome, not an antibody titer.
The catch is timing. Protection falls sharply with age at vaccination: 97% reduction in CIN3 for the 12-13 cohort versus 39% for the 16-18 cohort [4]. In the 30-34 catch-up group, the mortality estimate was imprecise and included no benefit at all [1]. The vaccine prevents new infections; it does not clear ones you already have [2].
| Group | Outcome | Reduction |
|---|---|---|
| Offered at 12-13 (England) | Invasive cervical cancer | 83.9% [3] |
| Offered at 12-13 (England) | CIN3 precancer | 94.3% [3] |
| Offered at 16-18 | CIN3 | 39% [4] |
| Catch-up, ages 30-34 | Cervical cancer death | 63%, range includes zero [1] |
Two honest caveats. The English studies are observational, comparing birth cohorts by vaccine offer, not individual vaccination status [3]. And the 2026 mortality finding compared observed deaths to a modeled historical counterfactual, not a real unvaccinated group [1]. The safety record rests on passive surveillance and committee reviews, not on long-term trials with hard endpoints [5][6].
My call: for a girl vaccinated before sexual exposure, the cancer reduction is real and large. For older women, the benefit is smaller and less certain. Confidence: moderate.
Sources used 6
-
HPV vaccination and cervical cancer deaths: from incidence reduction to mortality prevention
Narrative review concludes HPV vaccination is followed by population-level reductions in cervical cancer incidence and mortality, but the 2026 England mortality evidence is ecological and most precise in young cohorts.
DOI: 10.1007/s44272-026-00074-2 -
The Cervical Cancer (CC) Epidemiology and Human Papillomavirus (HPV) in the Middle East
A narrative review of cervical cancer and human papillomavirus (HPV) epidemiology in the Middle East (with emphasis on Iraq), detailing HPV genotype distribution, screening and vaccination strategies, regional disparities, and implications for prevention and public health.
DOI: 10.55151/ijeedu.v2i2.29 -
Effect of the HPV vaccination programme on incidence of cervical cancer and grade 3 cervical intraepithelial neoplasia by socioeconomic deprivation in England: population based observational study
In England, the HPV vaccination programme remained highly effective in July 2019-June 2020 and reduced cervical cancer and CIN3 incidence across all five socioeconomic deprivation fifths, flattening the cervical cancer deprivation gradient among vaccine-offered cohorts.
DOI: 10.1136/bmj-2023-077341 -
The Impact of Prophylactic HPV Vaccination on the Incidence of High-Grade Cervical Intraepithelial Neoplasia (CIN2/CIN3): A Systematic Review
This systematic review finds HPV vaccination provides substantial protection against cervical precancer/cancer, with evidence for one-dose schedules, cross-protection, and reduced effectiveness with older vaccination; findings are promising but mixed and do not challenge the ove…
DOI: 10.70070/kjmnzx32 -
Prophylactic HPV vaccination: past, present, and future
This review synthesizes evidence that prophylactic HPV vaccines (bivalent, quadrivalent, and 9-valent) demonstrate high efficacy and an excellent safety profile, with population-based programs already showing declines in HPV-related disease, supporting universal vaccination of y…
DOI: 10.1017/s0950268815002198 -
HPV vaccination and cancer prevention
Prophylactic HPV vaccines are highly effective against vaccine-type HPV infection and HPV-related disease, especially in HPV-naive prepubertal children; real-world data show population-level reductions and good safety, though older-woman vaccination is generally not cost-effecti…
DOI: 10.1016/j.bpobgyn.2020.02.009